company background image
ENZ logo

Enzo Biochem NYSE:ENZ Stock Report

Last Price

US$1.15

Market Cap

US$58.1m

7D

0.9%

1Y

-14.2%

Updated

30 Oct, 2024

Data

Company Financials

ENZ Stock Overview

Develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.

ENZ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Enzo Biochem, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzo Biochem
Historical stock prices
Current Share PriceUS$1.15
52 Week HighUS$1.50
52 Week LowUS$0.99
Beta0.73
11 Month Change2.68%
3 Month Change2.68%
1 Year Change-14.18%
33 Year Change-66.18%
5 Year Change-63.49%
Change since IPO-93.79%

Recent News & Updates

Enzo Biochem: Is This Time Finally Different?

Jul 17

Recent updates

Enzo Biochem: Is This Time Finally Different?

Jul 17

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

May 18
Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Jan 03
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Dec 12

Enzo Biochem appoints Patricia Eckert as interim CFO

Oct 20

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Oct 14

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Oct 04
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Jun 27

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

May 03
Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Dec 17
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Aug 24
Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Mar 01
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Feb 03
Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08
If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13
Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Shareholder Returns

ENZUS HealthcareUS Market
7D0.9%-0.5%0.5%
1Y-14.2%2.3%36.8%

Return vs Industry: ENZ underperformed the US Healthcare industry which returned 1.1% over the past year.

Return vs Market: ENZ underperformed the US Market which returned 38.6% over the past year.

Price Volatility

Is ENZ's price volatile compared to industry and market?
ENZ volatility
ENZ Average Weekly Movement3.5%
Healthcare Industry Average Movement6.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: ENZ has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ENZ's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976185Kara Cannonwww.enzo.com

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.

Enzo Biochem, Inc. Fundamentals Summary

How do Enzo Biochem's earnings and revenue compare to its market cap?
ENZ fundamental statistics
Market capUS$58.15m
Earnings (TTM)-US$9.82m
Revenue (TTM)US$31.91m

1.9x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENZ income statement (TTM)
RevenueUS$31.91m
Cost of RevenueUS$17.28m
Gross ProfitUS$14.63m
Other ExpensesUS$24.45m
Earnings-US$9.82m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin45.86%
Net Profit Margin-30.77%
Debt/Equity Ratio0.3%

How did ENZ perform over the long term?

See historical performance and comparison